Skip to main content
    G

    GRI Bio Inc. (GRI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.40
    -0.30 (-17.65%)

    Market Cap: $3.72M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    GRI Bio Inc. (GRI) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    GRI Bio reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$11.96M, operating cash flow was -$10.19M and free cash flow was -$10.19M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$1.51M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $11.98M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0-100.0%N/AN/AN/A
    Dec 2020$100.00KN/A100.0%-4788.0%-4822.0%
    Dec 2019N/AN/AN/AN/AN/A
    Dec 2018N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue$0$0$0$0$0$100.00KN/AN/A
    Cost of revenue$0$0$0$0$0$0$735$612
    Gross profit$0$0$0$0$0$100.00K-$735-$612
    Research and development$6.82M$3.77M$3.23M$242.00K$5.19M$3.71M$1.88M$3.51M
    Operating income-$11.98M-$8.23M-$11.39M-$2.24M-$9.26M-$4.79M-$3.15M-$4.31M
    Net income-$11.96M-$8.21M-$13.04M-$3.22M-$9.30M-$4.82M-$3.46M-$4.31M
    EBITDA-$11.97M-$8.23M-$9.10M-$2.02M-$9.09M-$4.71MN/A-$4.31M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$2.30M$0$0$0$5.39M
    Gross profit$0$0$0-$1.00K$0$0$0-$1.00K$0$0$0-$15.00K
    Operating income-$1.51M-$1.65M-$2.00M-$2.66M-$3.37M-$2.90M-$3.05M-$1.95M-$2.13M-$2.26M-$1.90M-$2.03M
    Net income-$1.51M-$1.64M-$2.00M-$2.66M-$3.36M-$2.89M-$3.05M-$1.95M-$2.12M-$2.25M-$1.89M-$2.00M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $56.00K by $8.17M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$8.67M$5.74M$2.96M$383.00K$8.34M$955.00K$4.28M$639.23K
    Current assets$8.59M$5.62M$2.93M$312.00K$8.13M$674.00K$3.92M$637.64K
    Cash and equivalents$8.23M$5.03M$1.81M$9.00K$3.70M$109.00K$3.82M$612.65K
    Total liabilities$2.66M$1.71M$2.70M$2.01M$2.52M$2.41M$1.06M$486.29K
    Short-term debt$56.00K$48.00K$14.00K$602.00K$3.55M$47.00K$85.67KN/A
    Long-term debtN/AN/AN/AN/AN/A$14.00KN/AN/A
    Shareholder equity$6.01M$4.03M$259.00K-$1.63M$5.82M-$1.45M$3.21M$152.94K
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$9.76M$11.38M$11.34M$8.67M$4.78M$5.67M$4.04M$5.74M$5.46M$7.03M$4.59M$2.96M
    Total liabilities$953.00K$1.10M$794.00K$2.66M$2.79M$2.35M$2.84M$1.71M$1.80M$2.31M$1.79M$2.70M
    Cash and equivalents$9.47M$10.95M$11.05M$8.23M$4.05M$5.12M$3.28M$5.03M$4.75M$6.35M$4.09M$1.81M
    Shareholder equity$8.81M$10.28M$10.54M$6.01M$1.99M$3.32M$1.21M$4.03M$3.66M$4.72M$2.80M$259.00K
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$10.19M-$8.61M-$8.99M-$1.08M-$8.31M-$3.71M-$2.88M-$2.37M
    Capital expenditures$3.00K$0$8.00K$3.00K$0$2.00K$5$2.21K
    Free cash flow-$10.19M-$8.61M-$9.00M-$1.09M-$8.31M-$3.71M-$2.88M-$2.37M
    Dividends paidN/AN/A$2.92M$3.45MN/AN/AN/AN/A
    Share repurchases$2.17M$2.03M$517.00K$111.00KN/AN/AN/AN/A
    Investing cash flow-$3.00K$0-$8.00K-$3.00K-$3.84M-$2.00KN/A-$2.20K
    Financing cash flow$13.39M$11.83M$10.80M$1.01M$15.75M-$4.00K$6.09M$2.99M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$1.48M-$1.45M-$3.69M-$2.97M-$2.31M-$3.17M-$1.74M-$2.00M-$2.27M-$2.14M-$2.20M-$5.56M
    Capital expendituresN/AN/A$0$3.00K$0$396.00K$0$0$0$0$0$0
    Free cash flowN/AN/A-$3.69M-$2.97M-$2.31M-$3.56M-$1.74M-$2.00M-$2.27M-$2.14M-$2.20M-$5.56M
    Last 12 quarters

    Frequently Asked Questions About GRI

    What is GRI Bio's annual revenue?

    GRI Bio reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is GRI Bio profitable?

    No. GRI Bio reported net income of -$11.96M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does GRI generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$10.19M minus capital expenditures of $3.00K produced free cash flow of -$10.19M.

    How much debt does GRI Bio have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $56.00K and cash and equivalents of $8.23M.